Terms: = Lymphoma AND IDH2, P48735, 3418, ENSG00000182054, IDHM, mNADP-IDH, IDH, IDP, ICD-M
207 results:
1. Liquid biopsy-based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results.
Mata DA; Lee JK; Shanmugam V; Marcus CB; Schrock AB; Williams EA; Ritterhouse LL; Hickman RA; Janovitz T; Patel NR; Kroger BR; Ross JS; Mirza KM; Oxnard GR; Vergilio JA; Elvin JA; Benhamida JK; Decker B; Xu ML
Histopathology; 2024 Jun; 84(7):1224-1237. PubMed ID: 38422618
[TBL] [Abstract] [Full Text] [Related]
2. Evaluation of Immunohistochemical Expression of ALK-1 in Gliomas, WHO Grade 4 and Its Correlation with idh1-R132H Mutation Status.
Khairy RA; Momtaz EM; Abd El Aziz AM; Shibel PEE
Asian Pac J Cancer Prev; 2024 Jan; 25(1):317-323. PubMed ID: 38285799
[TBL] [Abstract] [Full Text] [Related]
3. [Mutation characteristics of angioimmunoblastic T-cell lymphoma: an analysis of 75 cases].
Shen X; Yi HM; Li AQ; Ouyang BS; Dong L; Wang CF
Zhonghua Bing Li Xue Za Zhi; 2024 Jan; 53(1):29-33. PubMed ID: 38178743
[No Abstract] [Full Text] [Related]
4. Comparative evaluation of
Norikane T; Mitamura K; Yamamoto Y; Manabe Y; Murao M; Arai-Okuda H; Hatakeyama T; Miyake K; Nishiyama Y
J Neurooncol; 2024 Jan; 166(1):195-201. PubMed ID: 38160415
[TBL] [Abstract] [Full Text] [Related]
5. Clinical and histological study of follicular helper T-cell lymphomas with indolent evolution.
Messéant O; Drieux F; Sako N; Fataccioli V; Camus V; Robe C; Houot R; Tas P; Llamas-Gutierrez F; Lamaison C; Abraham J; Delage-Corre M; Benguerfi S; Bossard JB; Gaulard P; Lemonnier F
Eur J Cancer; 2024 Jan; 197():113479. PubMed ID: 38128263
[TBL] [Abstract] [Full Text] [Related]
6. Treatment regimens in patients over 64 years with acute myeloid leukaemia: a retrospective single-institution, multi-site analysis.
Sutter T; Schittenhelm M; Volken T; Lehmann T
Hematology; 2023 Dec; 28(1):2206694. PubMed ID: 38078486
[TBL] [Abstract] [Full Text] [Related]
7. Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and idh inhibitors.
Madero-Marroquin R; DuVall AS; Saygin C; Wang P; Gurbuxani S; Larson RA; Stock W; Patel AA
Br J Haematol; 2024 Apr; 204(4):1238-1242. PubMed ID: 38073116
[TBL] [Abstract] [Full Text] [Related]
8. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
9. Angioimmunoblastic T-cell lymphoma and Kaposi sarcoma: A fortuitous collision?
Poullot E; Milowich D; Lemonnier F; Bisig B; Robe C; Pelletier L; Letourneau A; Dupuy A; Sako N; Ketterer N; Carde P; Dartigues P; Delfau-Larue MH; de Leval L; Gaulard P
Histopathology; 2024 Feb; 84(3):556-564. PubMed ID: 37988271
[TBL] [Abstract] [Full Text] [Related]
10. Donor-Derived Malignancy and Transplantation Morbidity: Risks of Patient and Donor Genetics in Allogeneic Hematopoietic Stem Cell Transplantation.
Williams LS; Williams KM; Gillis N; Bolton K; Damm F; Deuitch NT; Farhadfar N; Gergis U; Keel SB; Michelis FV; Panch SR; Porter CC; Sucheston-Campbell L; Tamari R; Stefanski HE; Godley LA; Lai C
Transplant Cell Ther; 2024 Mar; 30(3):255-267. PubMed ID: 37913908
[TBL] [Abstract] [Full Text] [Related]
11. BCL2A1 is associated with tumor-associated macrophages and unfavorable prognosis in human gliomas.
Gao L; Ye Z; Peng S; Lei P; Song P; Li Z; Zhou L; Hua Q; Cheng L; Wei H; Liu J; Cai Q
Aging (Albany NY); 2023 Oct; 15(20):11611-11638. PubMed ID: 37889551
[TBL] [Abstract] [Full Text] [Related]
12. A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed idh2-mutant AML.
Cai SF; Huang Y; Lance JR; Mao HC; Dunbar AJ; McNulty SN; Druley T; Li Y; Baer MR; Stock W; Kovacsovics T; Blum WG; Schiller GJ; Olin RL; Foran JM; Litzow M; Lin T; Patel P; Foster MC; Boyiadzis M; Collins RH; Chervin J; Shoben A; Vergilio JA; Heerema NA; Rosenberg L; Chen TL; Yocum AO; Druggan F; Marcus S; Stefanos M; Druker BJ; Mims AS; Borate U; Burd A; Byrd JC; Levine RL; Stein EM
Blood Adv; 2024 Jan; 8(2):429-440. PubMed ID: 37871309
[TBL] [Abstract] [Full Text] [Related]
13. [TFH lymphoma and associated clonal hematopoiesis].
Nann D; Fend F; Quintanilla-Martinez L
Pathologie (Heidelb); 2023 Dec; 44(Suppl 3):144-149. PubMed ID: 37870568
[TBL] [Abstract] [Full Text] [Related]
14. Composite B-cell and T-cell lymphomas: clinical, pathological, and molecular features of three cases and literature review.
Jin X; Liu H; Li J; Xiao X; Yuan X; Chen P; Chen B; Liang Y; Huang F
J Zhejiang Univ Sci B; 2023 Aug; 24(8):711-722. PubMed ID: 37551557
[TBL] [Abstract] [Full Text] [Related]
15.
Babakhanlou R; DiNardo C; Borthakur G
Leuk Lymphoma; 2023; 64(11):1733-1741. PubMed ID: 37462435
[TBL] [Abstract] [Full Text] [Related]
16. Samples from patients with AML show high concordance in detection of mutations by NGS at local institutions vs central laboratories.
Borate U; Yang F; Press R; Ruppert AS; Jones D; Caruthers S; Zhao W; Vergilio JA; Pavlick DC; Juckett L; Norris B; Bucy T; Burd A; Stein EM; Patel P; Baer MR; Stock W; Schiller G; Blum W; Kovacsovics T; Litzow M; Foran J; Heerema NA; Rosenberg L; Marcus S; Yocum A; Stefanos M; Druker B; Byrd JC; Levine RL; Mims A
Blood Adv; 2023 Oct; 7(20):6048-6054. PubMed ID: 37459200
[TBL] [Abstract] [Full Text] [Related]
17. [Analysis of clinicopathological and molecular abnormalities of angioimmunoblastic T-cell lymphoma].
Shi YF; Wang HJ; Liu WP; Mi L; Long MP; Liu YF; Lai YM; Zhou LX; Diao XT; Li XH
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Jun; 55(3):521-529. PubMed ID: 37291929
[TBL] [Abstract] [Full Text] [Related]
18. EZH2 mediated metabolic rewiring promotes tumor growth independently of histone methyltransferase activity in ovarian cancer.
Chen J; Hong JH; Huang Y; Liu S; Yin J; Deng P; Sun Y; Yu Z; Zeng X; Xiao R; Chan JY; Guan P; Wang Y; Wang P; Liu L; Wen S; Yu Q; Ong CK; Teh BT; Xiong Y; Tan J
Mol Cancer; 2023 May; 22(1):85. PubMed ID: 37210576
[TBL] [Abstract] [Full Text] [Related]
19. SOHO State of the Art Updates and Next Questions | Accelerated Phase of MPN: What It Is and What to Do About It.
Patel AA; Odenike O
Clin Lymphoma Myeloma Leuk; 2023 May; 23(5):303-309. PubMed ID: 36907766
[TBL] [Abstract] [Full Text] [Related]
20. Gene Mutations and Targeted Therapies of Myeloid Sarcoma.
Fu L; Zhang Z; Chen Z; Fu J; Hong P; Feng W
Curr Treat Options Oncol; 2023 Apr; 24(4):338-352. PubMed ID: 36877373
[TBL] [Abstract] [Full Text] [Related]
[Next]